264 related articles for article (PubMed ID: 32346807)
1. Applying the New Guidelines of HER2 Testing in Breast Cancer.
Zhang H; Moisini I; Ajabnoor RM; Turner BM; Hicks DG
Curr Oncol Rep; 2020 Apr; 22(5):51. PubMed ID: 32346807
[TBL] [Abstract][Full Text] [Related]
2. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
[TBL] [Abstract][Full Text] [Related]
3. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
4. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
5. HER2 testing: current status and future directions.
Perez EA; Cortés J; Gonzalez-Angulo AM; Bartlett JM
Cancer Treat Rev; 2014 Mar; 40(2):276-84. PubMed ID: 24080154
[TBL] [Abstract][Full Text] [Related]
6. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
7. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
[TBL] [Abstract][Full Text] [Related]
8. Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory.
Gulbahce HE
Am J Clin Pathol; 2017 Oct; 148(4):308-313. PubMed ID: 28967951
[TBL] [Abstract][Full Text] [Related]
9. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
10. The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines.
Long TH; Lawce H; Durum C; Moore SR; Olson SB; Gatter K; Troxell ML
Am J Clin Pathol; 2015 Aug; 144(2):253-62. PubMed ID: 26185310
[TBL] [Abstract][Full Text] [Related]
11. [Re-evaluation of HER2 status in 1 501 invasive breast cancers according to the 2013 American Society of Clinical Oncology/College of American Pathology guidelines].
Zhang H; Zhang S; Wang Y; Li D; Xu L; Liu Q; Duan X; Liu Y; Li T
Zhonghua Bing Li Xue Za Zhi; 2015 Jan; 44(1):42-7. PubMed ID: 25765030
[TBL] [Abstract][Full Text] [Related]
12. Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.
Gordian-Arroyo AM; Zynger DL; Tozbikian GH
Am J Clin Pathol; 2019 Jun; 152(1):17-26. PubMed ID: 30958889
[TBL] [Abstract][Full Text] [Related]
13. [Impact of 2013 American Society of Clinical Oncology/College of American Pathologist guidelines on borderline immunostaining results for HER2: a retrospective study on HER2 FISH results in 1 780 cases of invasive breast cancers].
Xu Y; Bai QM; Yang F; Zhu XL; Lu YM; Zhang J; Yang WT; Zhou XY
Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):545-9. PubMed ID: 27510780
[TBL] [Abstract][Full Text] [Related]
14. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
15. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer.
Xu B; Shen J; Guo W; Zhao W; Zhuang Y; Wang L
Pathol Res Pract; 2019 Feb; 215(2):251-255. PubMed ID: 30420102
[TBL] [Abstract][Full Text] [Related]
16. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
[TBL] [Abstract][Full Text] [Related]
17. Assessing the impact of the 2018 American Society of Clinical Oncology/College of American Pathologists recommendations on human epidermal growth factor receptor 2 testing by fluorescence in situ hybridization in breast carcinoma.
Murray C; Flanagan L; D'Arcy C; Gullo G; Quinn CM
Virchows Arch; 2020 Mar; 476(3):367-372. PubMed ID: 31375912
[TBL] [Abstract][Full Text] [Related]
18. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
Middleton LP; Price KM; Puig P; Heydon LJ; Tarco E; Sneige N; Barr K; Deavers MT
Arch Pathol Lab Med; 2009 May; 133(5):775-80. PubMed ID: 19415952
[TBL] [Abstract][Full Text] [Related]
19. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
Shah MV; Wiktor AE; Meyer RG; Tenner KS; Ballman KV; Green SJ; Sukov WR; Ketterling RP; Perez EA; Jenkins RB
J Clin Oncol; 2016 Oct; 34(29):3502-3510. PubMed ID: 27458302
[TBL] [Abstract][Full Text] [Related]
20. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]